Form 4: BridgeBio Pharma Director Jennifer Cook Receives Equity Compensation Grant

BridgeBio Pharma, Inc. Director Jennifer E. Cook was granted Restricted Stock Units and stock options as part of her compensation, aligning her interests with the company's long-term performance.

Summary

• Jennifer E. Cook, a Director of BridgeBio Pharma, Inc. (BBIO), received an equity compensation grant on June 20, 2025.
• The grant includes 6,589 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of the Issuer's Common Stock per RSU.
• These RSUs will vest in three equal annual installments, with one-third vesting each year after June 20, 2025, and full vesting by June 20, 2028, contingent on her continued service on the board.
• Additionally, Ms. Cook was granted stock options to purchase 8,425 shares of Common Stock at an exercise price of $41.73 per share.
• Similar to the RSUs, these stock options will also vest one-third annually after June 20, 2025, fully vesting by June 20, 2028, subject to her continued board service.
• The stock options have an expiration date of June 19, 2035.
• Following these transactions, Jennifer E. Cook directly beneficially owns 13,741 shares of Common Stock and 8,425 stock options.
• The grants were made under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.

Sentiment

Score: 6

Explanation: This is a routine equity compensation grant to a director, which is a standard practice to align interests and retain talent. It is generally neutral to slightly positive as it reflects ongoing compensation practices and director commitment, rather than a significant financial event for the company.

Positives

• The equity grants align the director's financial interests with the long-term performance and shareholder value of BridgeBio Pharma, Inc.
• The grants indicate the continued commitment of Jennifer E. Cook to her role on the company's board of directors.

Future Outlook

The grants include a future vesting schedule for both Restricted Stock Units and stock options, with full vesting expected by June 20, 2028, contingent on the director's continued service.

Industry Context

This filing is a routine disclosure of director compensation through equity grants, a common practice across industries to incentivize long-term performance and align management/director interests with shareholders.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Jennifer E. Cook, a director of BridgeBio Pharma, Inc., constitutes a related party transaction as it involves compensation between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of equity awards, but also benefits from increased alignment of director's interests with long-term shareholder value.
• Employees: No direct impact from this specific director grant, but it reflects the company's broader approach to equity-based compensation.

Next Steps

• Continued annual vesting of the 6,589 Restricted Stock Units until fully vested on June 20, 2028.
• Continued annual vesting of the 8,425 stock options until fully vested on June 20, 2028.
• Jennifer E. Cook's continued service on the BridgeBio Pharma, Inc. board of directors is required for vesting.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Jennifer E. Cook, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Corporate Governance